- Programs & Services
- Cost Management
- Specialty Management
- Care Management
- Member Engagement
- Health Plan Client Engagement
The pipeline for gene therapies shows no signs of slowing and new treatments continue to be developed for conditions that had no cure or expand choices for those with limited options. In 2021 alone, multiple chimeric antigen receptor (CAR) T-cell therapies could be approved for several different cancers including two for multiple myeloma, as well as different types of lymphomas.
In our periodic gene therapy pipeline update report, we share information about treatments that may come up for review and approval by the U.S. Food and Drug Administration (FDA) in the near-term.
Treatments in the pipeline change often based on the success — or lack thereof — of clinical trials and other important data. We will continue to share updates to the gene therapy pipeline periodically.